Biotech News

Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals (RCKT)Rocket PharmaceuticalsEarnings

FDA alignment establishes path to complete the pivotal Phase 2 trial of RP-A501 in Danon disease; dosing completion expected by mid-2027 October Danon disease investor webinar highlighted updated longer-term RP-A501 Phase 1 findings and encouraging initial safety observations in the first three

Related news

Rocket Pharmaceuticals

Gene Therapies for Rare Disease Rocket Pharmaceuticals develops gene therapies for rare hematologic and cardiovascular disorders using lentiviral and adeno-associated-virus vectors. Commercial Hematology Franchise KRESLADI is an ex vivo lentiviral gene therapy approved for severe leukocyte adhesion deficiency type I. It represents...

Recent company news

Stock data

Close
2.11 USD
Market cap
315.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States